Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies
Phase of Trial: Phase III
Latest Information Update: 08 Oct 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms ZOSTER-039
- Sponsors GlaxoSmithKline
- 08 Oct 2017 Results presented at the IDWeek 2017.
- 18 May 2017 The trial has been completed in Sweden (end date: 6 Jan 2017).
- 21 Apr 2017 Status changed from active, no longer recruiting to completed.